Celea Therapeutics
Develops investigational therapies for serious respiratory diseases, including idiopathic pulmonary fibrosis
Highlights
- New on EvolcAdded 2026-11-14
Recent signals
What changed at Celea Therapeutics in the last 6 months, newest first. Each line links to its public source.
- 7 Oct 2026 Leadership hire · Hiring Director, Head of Corporate Communications (Boston) job-boards.greenhouse.io
About Celea Therapeutics
Celea Therapeutics develops deupirfenidone, an investigational antifibrotic therapy for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases. Its lead program is in Phase 3 development, and the company describes the treatment as an oral tablet.
The company was founded by PureTech Health. Its open roles are based in Boston and include positions in clinical development, regulatory affairs, IT, communications and legal.
Product: Deupirfenidone, an investigational oral antifibrotic therapy for idiopathic pulmonary fibrosis and other fibrotic lung diseases.
Jobs at Celea Therapeutics
Open roles at Celea Therapeutics in the Americas (2)
United States 2. From Celea Therapeutics's careers page or applicant tracking system; each role links to the employer.
- IT Systems Manager, AI Administration · Boston, United States
- Director, Head of Corporate Communications · Boston, United States
More biotech & pharma companies
Cellanome
Live-cell imaging and single-cell transcriptomics platform for biology research labs and biopharma companiesNew on EvolcCellarity
AI and multi-omics drug discovery of oral medicines that correct dysfunctional cell states in complex diseasesNew on EvolcCellular Intelligence
Develops AI and biology approaches to engineer cell fate for biomedical and drug-development applicationsNew on EvolcCentrillion Technologies
High-density DNA chips and molecular measurement platforms for life science researchers and diagnostic partnersNew on EvolcChai Discovery
AI-based molecular design tools for pharmaceutical and life sciences companies developing medicinesNew on EvolcClimb Bio
Develops monoclonal antibody medicines for people with immune-mediated diseasesNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Analytics 4High confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Content management
- SquarespaceHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Recruiting
- GreenhouseMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Page markupsoftware structure signature
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
